Roche’s seeming lack of confidence in the future of AT-527 appears to be weighing on investors. Atea shares, which soared above $88 in February 2021, …

Atea’s fast ascent last year was due to its plan to use a pill originally developed for hepatitis C infections as a treatment for COVID-19. …